Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;25(7):546-547.
doi: 10.1634/theoncologist.2020-0373. Epub 2020 Jun 5.

Training Oncologists in the Time of COVID-19

Noura Choudhury  1 , Alexander Shoushtari  1
Affiliations
Comment

Training Oncologists in the Time of COVID-19

Noura Choudhury et al. Oncologist. 2020 Jul.

Abstract

In this commentary, the authors explore the short‐ and long‐term challenges of balancing education and oncologic care from the epicenter of the COVID‐19 pandemic. Once local conditions allow for resumption of outpatient care, the authors discuss how now is an especially important time to prioritize educating trainees.

Keywords: Education; Oncologists; Pandemic.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Comment on

References

    1. Larkin J, Chiarion‐Sileni V, Gonzalez R et al. Five‐year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019;381:1535–1546. - PubMed
    1. Tawbi HA, Forsyth PA, Algazi A et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018;379:722–730. - PMC - PubMed
    1. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single‐agent anti‐programmed death‐1 (MDX‐1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167–3175. - PMC - PubMed
    1. CDC COVID‐19 Response Team . Severe outcomes among patients with coronavirus disease 2019 (COVID‐19)—United States, February 12‐March 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:343–346. - PMC - PubMed
    1. Shoushtari AN, Friedman CF, Navid‐Azarbaijani P et al. Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 2018;4:98–101. - PMC - PubMed